Zhe-Sheng (Jason) Chen
Basic info is private.
Interests
Cancer pharmacology; Drug discovery; Multidrug resistance (MDR)
Latest Publications
Open Access
Original Research
ABCB1 limits the cytotoxic activity of TAK-243, an inhibitor of the ubiquitin-activating enzyme UBA1
Zhuoxun Wu,
Yuqi Yang,
Zining Lei,
Silpa Narayanan, ... Zhesheng Chen
Front. Biosci. (Landmark Ed) 2022, 27(1), 005;
https://doi.org/10.31083/j.fbl2701005
(This article belongs to the Special Issue The Overcoming of Multidrug Resistance in Cancer: Mechanisms and Strategies)
25
Download
2
Citations
123
Views
Open Access
Original Research
Poly (ADP-ribose) polymerase (PARP) inhibitors as chemosensitizing compounds for the treatment of drug resistant cancers
Narayanan Silpa,
Teng Qiu-Xu,
Koya Jagadish,
Wang Jingquan, ... Chen Zhe-Sheng
J. Mol. Clin. Med. 2019, 2(3), 55–67;
https://doi.org/10.31083/j.jmcm.2019.03.0303
20
Download
1
Citations
56
Views
Open Access
Original Research
KIT and PDGFRA inhibitor avapritinib (BLU-285) overcomes ABCB1- and ABCBG2-mediated MDR in cancer cells
Gupta Pranav,
V. Ashar Yunali,
Teng Qiu-Xu,
Lei Zining, ... Chen Zhe-Sheng
J. Mol. Clin. Med. 2019, 2(3), 69–78;
https://doi.org/10.31083/j.jmcm.2019.03.0301
6
Download
34
Views